Clinical Trial Update: Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206) [Phase 2]

View source ↗

Summary

Phase 2 trial update for tilsolotolimod in combination with nivolumab and ipilimumab for solid tumors; status ACTIVE_NOT_RECRUITING.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)
• tilsotolimod (tilsotolimod)

Snippet

Sponsor: Idera Pharmaceuticals, Inc. | Conditions: Solid Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING